Biodesix Q1 2026: Revenue Momentum, Margin Uplift, and a 2026 Revenue Forecast That Keeps investors listening for the EPS clues

Key numbers at a glance

• Total revenue: $25.6 million in Q1 2026, up 42% year over year.
• Diagnostic Testing revenue: $22.3 million, +37% YoY; test volumes up 29% to 17,800; higher average revenue per test driven by expanded payer coverage and better revenue cycle management.
• Development Services revenue: $3.3 million, up 99% YoY, buoyed by ongoing contracts and new Development Services agreements.
• Gross margin: 84% in Q1 2026; excluding a one-time $0.4 million tax-related item, margin was 82%, a ~300 basis point improvement year over year.
• Operating expenses (excluding direct costs and expenses): $27.6 million for Q1 2026, up 18% YoY. Investment in sales, marketing, and G&A up 19% to support 42% revenue growth.
• Guidance: 2026 revenue forecast raised to a range of $108-114 million, with the midpoint signaling roughly 25% growth year over year.

By the numbers: where the money is coming from

Biodesix’s quarter underscores a two-pronged revenue engine. Diagnostic Testing remains the bulk of the business and delivered a solid 37% YoY gain on a 29% volume lift. The uptick in average revenue per test is attributed to broader payer coverage and a more efficient revenue cycle. Development Services nearly doubled the growth pace, up 99% YoY, supported by ongoing contracts and the addition of new service agreements. The combined effect is a healthy total revenue trajectory that the company caps with a raised revenue forecast for 2026.

Margins and cost discipline

The gross margin strength—84% for the quarter—helps offset rising operating costs. Subtract the one-time tax recovery of $0.4 million and the margin sits at 82%, still a meaningful improvement versus the prior year. Management flags that margin drivers include higher testing volumes, better AR management, and laboratory workflow optimizations. The takeaway: volume growth is translating into better unit economics, even as the company invests in growth initiatives.

Outlook and implications for the stock and peers

The 2026 revenue forecast of $108-114 million positions Biodesix for solid mid-teens to low-30s percent growth depending on the quarterly cadence and product mix. The midpoint implies roughly 25% growth, a respectable trajectory if the company can sustain the drivers (volume growth, payer access, and service agreements) into the rest of the year.

However, the press release stops short of presenting an EPS figure for the quarter, or an explicit EPS consensus from analysts. In other words, investors have a gap-filled lens: revenue growth and margin progress are encouraging, but the main question remains whether Biodesix can translate this top-line strength into a meaningful earnings per share metric in 2026. The absence of an EPS figure invites modelers to fill in assumptions, which can yield divergent outcomes and, occasionally, outsized post-earnings moves if the actual result diverges from those estimates.

What this portends for Biodesix’s peers

Biodesix’s mix—robust Diagnostics volume, expanding payer coverage, and a growing Development Services line—offers a blueprint for peers navigating a mixed-revenue environment where growth and profitability must coexist. If Biodesix can sustain gross-margin expansion amid continued S&M and G&A investments, the sector could see a re-rating of valuation multiples on improved unit economics rather than purely on top-line gyrations. For competitors, the takeaway is simple: monetize volumes efficiently, defend payer access, and temper investment pace so early-breakeven dynamics don’t turn into longer-than-expected burn trajectories.

Bottom line

Biodesix’s first quarter of 2026 demonstrates meaningful revenue acceleration and margin resilience that justify an upbeat revenue forecast for the year. The absence of an EPS figure in this release means the market will lean on consensus estimates and a few pointed questions to judge profitability momentum. For those watching BDSX, the question isn’t whether the company can grow; it’s whether the growth translates into earnings power in 2026 and beyond, and how the EPS trajectory compares to the EPS consensus currently baked into share prices. In short: the revenue story is convincing, the earnings story remains to be written—at least in a quarterly print that includes an EPS line item.